SLS (SELLAS Life Sciences Group) EBITDA Margin %: 0.00% (As of Mar. 2026)

What is SELLAS Life Sciences Group EBITDA Margin %?

SELLAS Life Sciences Group SLS +1.10% 25 EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus rates SLS with a GF Score™ of 25/100. The stock has 1 warning sign investors should review. Among 945 Biotechnology companies, SELLAS Life Sciences Group ranks worse than 105820% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. SELLAS Life Sciences Group's EBITDA for the three months ended in Mar. 2026 was $-9.25 Mil. SELLAS Life Sciences Group's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, SELLAS Life Sciences Group's EBITDA margin for the quarter that ended in Mar. 2026 was 0.00%.

SELLAS Life Sciences Group (NAS:SLS) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

SELLAS Life Sciences Group EBITDA Margin % Related Terms

SELLAS Life Sciences Group EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for SELLAS Life Sciences Group's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SELLAS Life Sciences Group EBITDA Margin % Chart

SELLAS Life Sciences Group Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

EBITDA Margin %

Get a 7-Day Free Trial

-257.82

-3,195.00

0.00

SELLAS Life Sciences Group Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
EBITDA Margin %	Get a 7-Day Free Trial															0.00	0.00	0.00	0.00	0.00

SLS vs SNDX, CAPR, AGIO: EBITDA Margin % Comparison

For the Biotechnology subindustry, SELLAS Life Sciences Group's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

SELLAS Life Sciences Group EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SELLAS Life Sciences Group's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where SELLAS Life Sciences Group's EBITDA Margin % falls into.

Save Embed

25GF Score

SELLAS Life Sciences Group Inc SLS

EBITDA Margin % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

SELLAS Life Sciences Group EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

SELLAS Life Sciences Group's EBITDA Margin % for the fiscal year that ended in Dec. 2025 is calculated as

EBITDA Margin %	=	EBITDA (A: Dec. 2025 )	/	Revenue (A: Dec. 2025 )
	=	-28.274	/	0
	=	%

SELLAS Life Sciences Group's EBITDA Margin % for the quarter that ended in Mar. 2026 is calculated as

EBITDA Margin %	=	EBITDA (Q: Mar. 2026 )	/	Revenue (Q: Mar. 2026 )
	=	-9.252	/	0
	=	%

Frequently Asked Questions Learn more about EBITDA Margin % →

What does a EBITDA Margin % of 0.00% mean?

SELLAS Life Sciences Group (SLS) has a EBITDA Margin % of 0.00% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on SELLAS Life Sciences Group and its competitors. According to the industry distribution chart, SELLAS Life Sciences Group ranks #999999 out of 945 companies in the Biotechnology industry.

Is SELLAS Life Sciences Group's EBITDA Margin % too high?

SELLAS Life Sciences Group's current EBITDA Margin % is 0.00%. Based on the distribution chart, SELLAS Life Sciences Group ranks #999999 out of 945 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, SELLAS Life Sciences Group has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.

How does SELLAS Life Sciences Group's EBITDA Margin % compare to SNDX and CAPR?

According to the Biotechnology industry distribution chart, SELLAS Life Sciences Group ranks #999999 out of 945 companies for EBITDA Margin %. This places SELLAS Life Sciences Group in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EBITDA Margin % for a Biotechnology company?

A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EBITDA Margin % mean?

A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on SELLAS Life Sciences Group and its competitors. SELLAS Life Sciences Group's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is SELLAS Life Sciences Group stock overvalued right now?

SELLAS Life Sciences Group (SLS) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. SELLAS Life Sciences Group's overall GF Score™ is 25/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EBITDA Margin % calculated?

EBITDA Margin % is calculated from a company's financial statements. For SELLAS Life Sciences Group (SLS), the current EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

SELLAS Life Sciences Group Business Description

Industry Healthcare Biotechnology

Comparable Companies SNDX CAPR AGIO VCEL PVLA TSHA GENB ATAI GLUE NUVB VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Other Exchanges RXK3:Germany

Address 7 Times Square, Suite 2503, New York, NY, USA, 10036

Website https://www.sellaslifesciences.com

SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.

25GF Score

Get the complete analysis for SLS

EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$9.17

Price

View SLS Analysis

See EBITDA Margin % data for all stocks →